Henri Salle1,2, Elise Deluche3, Elodie Couvé-Deacon4, Anne-Claire Beaujeux5, Johan Pallud6,7, Alexandre Roux6,7, Arnaud Dagain8, Amaury de Barros9, Jimmy Voirin10,11, Romuald Seizeur12,13, Houda Belmabrouk12, Leslie Lemnos5, Evelyne Emery14,15, Marie-Jeanne Fotso16, Julien Engelhardt17, Vincent Jecko17,18, Ilyess Zemmoura19,20, Tuan Le Van21, Moncef Berhouma22,23, Hélène Cebula11, Matthieu Peyre24,25, Pierre-Marie Preux26, François Caire5,27. 1. Neurochirurgie, CHU de Limoges, Limoges, France. henrisalle1@gmail.com. 2. CAPTuR, EA 3842, Université de Limoges, Limoges, France. henrisalle1@gmail.com. 3. Oncologie médicale, CHU de Limoges, Limoges, France. 4. Hygiène, CHU de Limoges, Limoges, France. 5. Neurochirurgie, CHU de Limoges, Limoges, France. 6. Neurochirurgie, GHU Paris - Hôpital Sainte-Anne, Paris, France. 7. IMA-BRAIN, UMR1266, Inserm, Paris, France. 8. Neurochirurgie, BCRM Toulon, HIA Sainte-Anne, Toulon, France. 9. Neurochirurgie, CHU de Toulouse, Hopital Pierre-Paul Riquet, Toulouse, France. 10. Neurochirurgie, Hôpitaux Civils de Colmar, Colmar, France. 11. Neurochirurgie, CHU de Strasbourg, Strasbourg, France. 12. Neurochirurgie, Hôpital de La Cavale Blanche, CHU de Brest, Brest, France. 13. Université de BREST, LaTIM INSERM UMR 1101, Brest, France. 14. Neurochirurgie, CHU Caen Normandie, Caen, France. 15. Université CAEN Normandie, Inserm U 12 37, Cycéron, Caen, France. 16. Neurochirurgie, CHU de Saint-Etienne, Saint-Etienne, France. 17. Neurochirurgie, CHU de Bordeaux, Bordeaux, France. 18. INCIA, UMR 5287, Université de Bordeaux, CNRS, Bordeaux, France. 19. Neurochirurgie, CHU de Tours, Tours, France. 20. iBrain, UMR 1253, Université de Tours, Inserm, Tours, France. 21. Neurochirurgie, CHU de Dijon, Dijon, France. 22. Neurochirurgie, CHU de Lyon, Hôpital Neurologique Pierre Wertheimer, Lyon, France. 23. Creatis Laboratory, , CNRS UMR 5220, INSERM U1206, Université Lyon 1/INSA, Lyon, France. 24. Neurochirurgie, APHP, Groupe Hospitalier Pitié Salpêtrière, Paris, France. 25. Genetics and Development of Brain Tumors - CRICM INSERM U1127 CNRS UMR 7225, Paris, France. 26. Centre d'Epidémiologie, CHU de Limoges, de Biostatistiques Et de Méthodologie de La Recherche CEBIMER, Limoges, France. 27. XLIM, UMR 7252, Université de Limoges, CNRS, Limoges, France.
Abstract
BACKGROUND: The effects of surgical site infections (SSI) after glioblastoma surgery on patient outcomes are understudied. The aim of this retrospective multicenter study was to evaluate the impact of SSI on the survival of glioblastoma patients. METHODS: Data from SSI cases after glioblastoma surgeries between 2009 and 2016 were collected from 14 French neurosurgical centers. Collected data included patient demographics, previous medical history, risk factors, details of the surgical procedure, radiotherapy/chemotherapy, infection characteristics, and infection management. Similar data were collected from gender- and age-paired control individuals. RESULTS: We used the medical records of 77 SSI patients and 58 control individuals. 13 were excluded. Our analyses included data from 64 SSI cases and 58 non-infected glioblastoma patients. Infections occurred after surgery for primary tumors in 38 cases (group I) and after surgery for a recurrent tumor in 26 cases (group II). Median survival was 381, 633, and 547 days in patients of group I, group II, and the control group, respectively. Patients in group I had significantly shorter survival compared to the other two groups (p < 0.05). The one-year survival rate of patients who developed infections after surgery for primary tumors was 50%. Additionally, we found that SSIs led to postoperative treatment discontinuation in 30% of the patients. DISCUSSION: Our findings highlighted the severity of SSIs after glioblastoma surgery, as they significantly affect patient survival. The establishment of preventive measures, as well as guidelines for the management of SSIs, is of high clinical importance.
BACKGROUND: The effects of surgical site infections (SSI) after glioblastoma surgery on patient outcomes are understudied. The aim of this retrospective multicenter study was to evaluate the impact of SSI on the survival of glioblastomapatients. METHODS: Data from SSI cases after glioblastoma surgeries between 2009 and 2016 were collected from 14 French neurosurgical centers. Collected data included patient demographics, previous medical history, risk factors, details of the surgical procedure, radiotherapy/chemotherapy, infection characteristics, and infection management. Similar data were collected from gender- and age-paired control individuals. RESULTS: We used the medical records of 77 SSI patients and 58 control individuals. 13 were excluded. Our analyses included data from 64 SSI cases and 58 non-infectedglioblastomapatients. Infections occurred after surgery for primary tumors in 38 cases (group I) and after surgery for a recurrent tumor in 26 cases (group II). Median survival was 381, 633, and 547 days in patients of group I, group II, and the control group, respectively. Patients in group I had significantly shorter survival compared to the other two groups (p < 0.05). The one-year survival rate of patients who developed infections after surgery for primary tumors was 50%. Additionally, we found that SSIs led to postoperative treatment discontinuation in 30% of the patients. DISCUSSION: Our findings highlighted the severity of SSIs after glioblastoma surgery, as they significantly affect patient survival. The establishment of preventive measures, as well as guidelines for the management of SSIs, is of high clinical importance.
Authors: Hsiu-Yin Chiang; Aparna S Kamath; Jean M Pottinger; Jeremy D W Greenlee; Matthew A Howard; Joseph E Cavanaugh; Loreen A Herwaldt Journal: J Neurosurg Date: 2013-11-08 Impact factor: 5.115
Authors: Kingsley O Abode-Iyamah; Hsiu-Yin Chiang; Nolan Winslow; Brian Park; Mario Zanaty; Brian J Dlouhy; Oliver E Flouty; Zachary D Rasmussen; Loreen A Herwaldt; Jeremy D Greenlee Journal: J Neurosurg Date: 2017-05-12 Impact factor: 5.115
Authors: Michael Karsy; Nam Yoon; Lillian Boettcher; Randy Jensen; Lubdha Shah; Joel MacDonald; Sarah T Menacho Journal: J Neurooncol Date: 2018-02-01 Impact factor: 4.130
Authors: Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2020-03-09 Impact factor: 4.130